Compare Pure Storage (P) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pure Storage vs Travere Therapeutics Inc. Common Stock — how do they compare? Pure Storage trades at $137.99 (market cap $52.31B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Pure Storage is far larger — about 10.7× Travere Therapeutics Inc. Common Stock's market cap, and Pure Storage is trading nearer its 52-week high, Travere Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Pure Storage for 4 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| P | TVTX | |
|---|---|---|
Market Cap | $52.31B | $4.88B |
Volume | 3,373,937 | 1,668,577 |
Sector | Technology | Health |
52-Week High | $156.97 | $67.52 |
52-Week Low | $56.99 | $26.79 |
Typical Hold Time | 4 Days | 0 Days |
Enterprise Value | $51.52B | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Everpure (P) trades at $156.97, up 1.07% today, near its 52-week high. The stock shows strong momentum with a bullish technical signal, supported by three consecutive quarterly earnings beats. Revenue grew from $3.17B in 2025 to $4.3B in 2026, with net income more than doubling. Recent news highlights a 147% six-month surge driven by AI-driven growth targets and positive investor sentiment.
Outlook remains optimistic due to robust earnings performance and AI expansion plans, but high valuation multiples (P/E 215) and overbought technical indicators pose risks. Analyst consensus is strongly bullish with a $141.47 price target, though insider selling and competitive pressures warrant caution for new investments.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Pure Storage
Pure Storage develops enterprise data storage and data management systems, primarily using all-flash technology. Its platform supports cloud, AI, analytics, and mission-critical application workloads.
Read more on P →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
